接受177Lu标记PSMA靶向放射性配体治疗的mCRPC患者4周与6周治疗间隔的配对分析
这项回顾性配对分析比较mCRPC患者接受177Lu-PSMA-RLT的4周与6周治疗间隔,4周组PSA缓解率及PSA-PFS有改善趋势但未达统计学显著,总生存无显著差异,4周组白细胞和血小板下降显著更明显,总体获益仍不确定,需进一步前瞻性研究。
要点
- 4周组PSA缓解率47.8% vs 6周组21.7%(p=0.12),差异未达统计学显著。
- 4周组中位PSA-PFS 26.0周 vs 6周组18.0周(HR 0.6;p=0.2),未达统计学显著。
- 4周组白细胞和血小板下降显著多于6周组(38.5% vs 18.2%,p=0.047;26.7% vs 10.7%,p=0.02)。
核心结论
- 将治疗间隔从6周缩短至4周在PSA缓解和PSA-PFS方面显示一定改善,但未显著影响总生存。
- 强化方案使骨髓储备显著降低,总体获益仍不确定,需进一步前瞻性研究比较4周与6周间隔的毒性、治疗反应和结局。
研究设计与样本
- 回顾性配对分析,比较接受177Lu-PSMA-RLT的mCRPC患者4周与6周治疗间隔队列的治疗毒性、PSA反应、PSA-PFS和总生存。
主要发现
- PSA缓解(PSA下降≥50%)在4周组和6周组分别为47.8%和21.7%(p=0.12)。
- 4周组较6周组中位PSA-PFS有延长趋势(26.0周 vs 18.0周;HR 0.6;p=0.2)。
- 4周组较6周组中位总生存有缩短趋势(15.1个月 vs 18.4个月;HR 1.3;p=0.5),未达统计学显著。
- 4周组较6周组白细胞和血小板计数下降显著更多(38.5% vs 18.2%,p=0.047;26.7% vs 10.7%,p=0.02)。
- 两组严重不良事件均较少。
局限性
- 原文为回顾性分析。
- 总体获益仍不确定,需进一步前瞻性研究比较4周与6周间隔的毒性、治疗反应和结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high disease volume and rapid progression. This retrospective analysis evaluated treatment toxicity, PSA response, PSA-progression-free survival (PSA-PFS), and overall survival (OS) in matched cohorts of mCRPC patients receiving 177Lu-PSMA-RLT at 4-week versus 6-week intervals. RESULTS: A PSA response (PSA decline ≥ 50%) was achieved in 47.8% and 21.7% of patients in the 4-week and 6-week treatment interval groups, respectively (p = 0.12). There was a trend towards longer PSA-PFS in the 4-week group compared to the 6-week group (median PSA-PFS, 26.0 weeks vs. 18.0 weeks; HR 0.6; p = 0.2). Although not statistically significant, there was a trend towards shorter OS in the 4-week group compared to the 6-week group (median OS, 15.1 months vs. 18.4 months; HR 1.3; p = 0.5). The 4-week group had a significantly greater decrease in leucocyte and platelet counts compared to the 6-week group (38.5% vs. 18.2% and 26.7% vs. 10.7%; p = 0.047 and p = 0.02). Severe adverse events were modest in both groups. CONCLUSIONS: Intensifying treatment intervals from 6 weeks to 4 weeks showed some improvements in PSA response and PSA-PFS for mCRPC patients, but did not significantly affect OS. Additionally, bone marrow reserve was significantly reduced with the intensified regimen. Therefore, the overall benefit remains uncertain, and further prospective studies are needed to compare 4-week and 6-week intervals regarding toxicity, treatment response, and outcome.
引用
- Karimzadeh A, Hecker CS, Heck MM, et al. Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval. EJNMMI Res. 2024. PMID: 39402311. doi:10.1186/s13550-024-01143-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。